BioDlink International Co Ltd
01875
Company Profile
Business description
BioDlink International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families, as well as medical professionals. The company has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The company generates maximum revenues from Mainland China.
Contact
120 Changyang Street
Suzhou Industrial Park
Suzhou215024
CHNT: +86 51262965186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
604
Stocks News & Analysis
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.60 | 9.20 | 0.10% |
| CAC 40 | 7,880.87 | 10.19 | 0.13% |
| DAX 40 | 23,745.06 | 5.59 | 0.02% |
| Dow JONES (US) | 46,316.07 | 68.78 | 0.15% |
| FTSE 100 | 9,299.84 | 15.01 | 0.16% |
| HKSE | 26,622.88 | 494.68 | 1.89% |
| NASDAQ | 22,591.15 | 107.09 | 0.48% |
| Nikkei 225 | 44,910.57 | 133.18 | -0.30% |
| NZX 50 Index | 13,157.68 | 25.12 | 0.19% |
| S&P 500 | 6,661.21 | 17.51 | 0.26% |
| S&P/ASX 200 | 8,880.40 | 11.10 | 0.13% |
| SSE Composite Index | 3,862.53 | 34.43 | 0.90% |